Ocugen (OCGN) Cash from Operations Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 37.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 16.64% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -7.60% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 34.32% |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | -6.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.11% |
| Dec 31, 2025 | 6.20% |
| Sep 30, 2025 | 3.34% |
| Jun 30, 2025 | 8.04% |
| Mar 31, 2025 | -8.71% |
| Dec 31, 2024 | 6.80% |
| Sep 30, 2024 | -11.86% |
| Jun 30, 2024 | 23.11% |
| Mar 31, 2024 | -26.11% |
| Dec 31, 2023 | -38.19% |
| Sep 30, 2023 | -72.87% |
| Jun 30, 2023 | -82.64% |
| Mar 31, 2023 | -57.30% |
| Dec 31, 2022 | -24.60% |
| Sep 30, 2022 | -89.00% |
| Jun 30, 2022 | -60.07% |
| Mar 31, 2022 | -78.09% |
| Dec 31, 2021 | -66.26% |
| Sep 30, 2021 | -5.20% |
| Jun 30, 2021 | -61.11% |
| Mar 31, 2021 | -53.37% |
| Dec 31, 2020 | 0.28% |
| Sep 30, 2020 | 22.62% |
| Jun 30, 2020 | 18.15% |
| Mar 31, 2020 | 13.91% |
| Dec 31, 2019 | -14.06% |
| Sep 30, 2019 | 27.06% |
| Jun 30, 2019 | 19.89% |
| Mar 31, 2019 | 30.19% |
| Dec 31, 2018 | 26.43% |
| Sep 30, 2018 | -0.17% |
| Jun 30, 2018 | 11.28% |
| Mar 31, 2018 | 33.48% |
| Dec 31, 2017 | 2.63% |
| Sep 30, 2017 | -27.01% |
| Jun 30, 2017 | -1.11% |
| Mar 31, 2017 | -13.53% |